Ghabili, Kamyar
Park, Henry S.
Yu, James B.
Sprenkle, Preston C.
Kim, Simon P.
Nguyen, Kevin A.
Ma, Xiaomei
Gross, Cary P.
Leapman, Michael S.
Funding for this research was provided by:
National Institutes of Health (K08CA237872)
Article History
Received: 10 March 2020
Accepted: 3 June 2020
First Online: 19 June 2020
Compliance with ethical standards
:
: Dr. Park has received honoraria from Varian Medical Systems, Inc., and Rad Onc Queestions, LLC. Dr. Yu has received research funding from 21st Century Oncology, and consulting fees from Augmenix Inc. Dr. Sprenkle serves as a consultant for Boston Scientific and GenomeDx Biosciences. Dr. Ma has received research funding from Celgene Corp. Dr. Gross has received research funding from NCCN/Pfizer, and travel funding from Flatiron, and funding from Johnson & Johnson to help design new approaches for sharing clinical trial data. Dr. Leaspman has received research funding from BESO Biologic. Dr. Ghabili, Mr. Nguyen, and Dr. Kim declare no potential conflict of interest.